David John Blackbourn PhD FRSB is currently professor of virology and director of the Institute of Medical Sciences at the University of Aberdeen.
[1] He is also a co-founder of Ducentis BioTherapeutics to produce a novel anti-inflammatory therapeutic drug and until September 2022, was non-executive board member.
[2] Under Ronald Chuang, PhD, he became a postdoctoral researcher at University of California, Davis in 1990 working on immune responses to Simian Immunodeficiency Virus (SIV).
In 1993, after Davis, he moved to University of California, San Francisco, again as a postdoctoral researcher, this time in the lab of Jay A.
[3] After his time at Surrey, in 2022 he moved to the University of Aberdeen as professor of virology and director of the Institute of Medical Sciences.